HEART rate variability biofeedback for long COVID symptoms (HEARTLOC): protocol for a feasibility study
Introduction
Long COVID (LC), also known as post-COVID-19 syndrome, refers to symptoms persisting 12 weeks after COVID-19 infection. It affects up to one in seven people contracting the illness and causes a wide range of symptoms, including fatigue, breathlessness, palpitations, dizziness, pain and brain fog. Many of these symptoms can be linked to dysautonomia or dysregulation of the autonomic nervous system after SARS-CoV2 infection. This study aims to test the feasibility and estimate the efficacy, of the heart rate variability biofeedback (HRV-B) technique via a standardised slow diaphragmatic breathing programme in individuals with LC.
Methods and analysis
30 adult LC patients with symptoms of palpitations or dizziness and an abnormal NASA Lean Test will be selected from a specialist Long COVID rehabilitation service. They will undergo a 4-week HRV-B intervention using a Polar chest strap device linked to the Elite HRV phone application while undertaking the breathing exercise technique for two 10 min periods everyday for at least 5 days a week. Quantitative data will be gathered during the study period using: HRV data from the chest strap and wrist-worn Fitbit, the modified COVID-19 Yorkshire Rehabilitation Scale, Composite Autonomic Symptom Score, WHO Disability Assessment Schedule and EQ-5D-5L health-related quality of life measures. Qualitative feedback on user experience and feasibility of using the technology in a home setting will also be gathered. Standard statistical tests for correlation and significant difference will be used to analyse the quantitate data.
Ethics and dissemination
The study has received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271). Dissemination plans include academic and lay publications.
Trial registration number
Top-30
Journals
|
1
|
|
|
Entropy
1 publication, 8.33%
|
|
|
Journal of Cardiovascular Development and Disease
1 publication, 8.33%
|
|
|
Journal of Medical Virology
1 publication, 8.33%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 8.33%
|
|
|
Nature Reviews Neurology
1 publication, 8.33%
|
|
|
Asian Bioethics Review
1 publication, 8.33%
|
|
|
Advances in Rehabilitation Science and Practice
1 publication, 8.33%
|
|
|
European Archives of Psychiatry and Clinical Neuroscience
1 publication, 8.33%
|
|
|
American Journal of Medicine
1 publication, 8.33%
|
|
|
Journal of The Korean Society of Physical Medicine
1 publication, 8.33%
|
|
|
Bioelectronic Medicine
1 publication, 8.33%
|
|
|
1
|
Publishers
|
1
2
3
4
|
|
|
Springer Nature
4 publications, 33.33%
|
|
|
MDPI
2 publications, 16.67%
|
|
|
Wiley
1 publication, 8.33%
|
|
|
Frontiers Media S.A.
1 publication, 8.33%
|
|
|
SAGE
1 publication, 8.33%
|
|
|
Elsevier
1 publication, 8.33%
|
|
|
The Korean Society of Physical Medicine
1 publication, 8.33%
|
|
|
1
2
3
4
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.